Dr. Spero Cataland

The Relationship of Complement Activation to Clinical Outcomes in Patients with Acquired Thrombotic Thrombocytopenic Purpura Mediated by Severe ADAMTS13 Deficiency

Dr. Spero Cataland, M.D.

Research Aims of this Study:

"The complement system is one important component of our immune system that is known to be central to the cause of atypical hemolytic uremic syndrome (aHUS). There has been evidence recently that shows this same complement system is involved in TTP as well. Our research is dedicated to studying the role of the complement system in the initiation of an acute TTP episode, the early and late recurrence of a TTP episode, and the risk of dying from an acute episode of TTP."

 

How Dr. Cataland believes this research will impact individuals living with or impacted by TTP:

"I believe this research will ultimately benefit many patients diagnosed with TTP.  Whether it may be during their initial treatment, or during a sustained remission, they hope that the information that is gained will help to better predict future clinical outcomes, but more importantly afford the ability to intervene clinically to improve the care of patients diagnosed with TTP."

How Dr. Cataland became interested in TTP research:

"I joined the faculty of Ohio State University in July 2000 and was directly in charge of the care of patients with TTP, he began to ask questions regarding the treatment of these patients for which there seemed to be no clear answers. Shortly thereafter he was pointed in the direction of Dr. James George who encouraged and mentored him to find answers to these same questions that he had been asking. Dr. Cataland believes that he owes Dr. George an incredible debt of gratitude for his help and assistance that still continues to this day."

Comments from Dr. Cataland to donors:

"It is difficult to put into words the appreciation that we have for the donors that have supported and continue support our research into acquired TTP.  In the past several years there have been significant advances in our understanding of the diagnosis and treatment of this rare disorder.  Without question I believe these advances will translate in the very near future into improvements in both short and long term patient outcomes for all patients diagnosed with TTP.  None of this progress would be possible without the generous support and involvement of the many donors to the Answering TTP Foundation."